In the last trading session, 4.05 million Acadia Pharmaceuticals Inc (NASDAQ:ACAD) shares changed hands as the company’s beta touched 0.69. With the company’s per share price at $21.99 changed hands at -$0.27 or -1.21% during last session, the market valuation stood at $3.68B. ACAD’s last price was a discount, traded about -14.73% off its 52-week high of $25.23. The share price had its 52-week low at $13.40, which suggests the last value was 39.06% up since then.
Analysts gave the Acadia Pharmaceuticals Inc (ACAD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.95. If we narrow down to specifics, the data shows that 1 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ACAD as a Hold, 14 felt it is a Buy and 0 rated the stock as Underweight.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
Instantly ACAD was in red as seen at the end of in last trading. With action 25.51%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 19.84%, with the 5-day performance at 25.51% in the green. However, in the 30-day time frame, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is 49.29% up.
The consensus price target for the stock as assigned by Wall Street analysts is 26, meaning bulls need an upside of 15.42% from its current market value. According to analyst projections, ACAD’s forecast low is 20 with 32 as the target high. To hit the forecast high, the stock’s price needs a -45.52% plunge from its current level, while the stock would need to tank 9.05% for it to hit the projected low.
Acadia Pharmaceuticals Inc (ACAD) estimates and forecasts
The 2025 estimates are for Acadia Pharmaceuticals Inc earnings to decrease by -61.77%, but the outlook for the next 5-year period is at 4.12% per year.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.2827% or 13.71 million shares worth $222.82 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 7.61 shares estimated at $167.42 million under it, the former controlled 4.55% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.30% of the shares, roughly 3.85 shares worth around $84.63 million.
